Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOQ81Y)

Drug Name
Vernakalant Drug Info
Synonyms
Vernakalant; 794466-70-9; UNII-9G468C8B13; Vemakalant; RSD1235; 9G468C8B13; (3R)-1-((1R,2R)-2-(2-(3,4-dimethoxyphenyl)ethoxy)cyclohexyl)pyrrolidin-3-ol; 3-Pyrrolidinol,1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]-, (3R)-; RSD-1235; Vernakalant [INN:BAN]; SCHEMBL410062; CHEMBL2111112; DTXSID60229659; VBHQKCBVWWUUKN-KZNAEPCWSA-N; CHEBI:135956; EX-A2465; ZINC22010910; 4151AH; AKOS027326205; DB06217; SB16873; CS-0276; API0014187; RL05068; 3-Pyrrolidinol, 1-((1R,2R)-2-(2-(3,4-dimethoxyphenyl)ethoxy)cyclohexyl)-, (3R)-
Indication
Disease Entry ICD 11 Status REF
Atrial fibrillation BC81.3 Phase 3 [1]
Cross-matching ID
PubChem CID
9930049
ChEBI ID
CHEBI:135956
CAS Number
CAS 794466-70-9
TTD Drug ID
DMOQ81Y
INTEDE Drug ID
DR1682

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DME
Drug Status:
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [3]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [4]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [5]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [6]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [7]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [8]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [9]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [10]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [11]
Propranolol DM79NTF Angina pectoris BA40 Approved [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6) Main DME DECB0K3 CP2D6_HUMAN Substrate [2]

References

1 Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008 Mar 25;117(12):1518-25.
2 Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors. J Clin Pharmacol. 2009 Jan;49(1):17-29.
3 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
4 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
5 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
6 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
7 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
8 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
9 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
10 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
11 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
12 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.